Gyeongnam Pharmaceutical Supplies 'Ringer Light Solution' to Universities and General Hospitals Nationwide

[Asia Economy Reporter Hyunseok Yoo] Gyeongnam Pharmaceutical announced on the 25th that it plans to supply Ringer Light Solution, for which it holds the exclusive domestic approval, to university hospitals and general hospitals nationwide in early next month.

Ringer Light Solution is an oral medication indicated for the supply and maintenance of fluids and electrolytes, containing glucose, sodium chloride, potassium citrate hydrate, and other ingredients as a prescription drug.

Gyeongnam Pharmaceutical obtained the exclusive domestic approval for the oral type of Ringer Light Solution, which can quickly and conveniently supply fluids and electrolytes, in December last year.

Gyeongnam Pharmaceutical plans to supply the oral fluid solution 'Ringer Light Solution,' which has shown effectiveness against adverse reactions after COVID-19 vaccination, to multiple university and general hospitals including Asan Medical Center, Seoul National University Hospital, Samsung Medical Center, Jeonbuk National University Hospital, and Severance Hospital.

A company representative stated, "While intravenous fluid solutions are administered through face-to-face contact by nurses or doctors, this oral fluid solution can be taken directly by patients in a non-face-to-face manner upon a doctor's prescription, significantly reducing risk. In particular, starting from the 1st of next month, it will be listed on the domestic insurance drug price list, which will reduce the patient's drug cost burden when prescribed."